Get started
Author

Laurence Simon

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
2016 · Monique C. Minnema, Eva Kimby, et al. · Haematologica · 150
PDF
Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).
2015 · L. Simon, A. Fitsiori, et al. · Haematologica · 145
PDF
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC
2015 · Flore Sicre de Fontbrune, Claire Galambrun, et al. · Transplantation · 131
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies
2020 · Marie Le Cann, Françoise Bouhour, et al. · Blood · 74
PDF
[Complementary and alternative medicines taken by cancer patients].
2007 · L Simon, D Prebay, et al. · PubMed · 66
Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia
2018 · Adrien Contejean, Matthieu Resche-Rigon, et al. · Haematologica · 37
PDF
Imaging spectrum of Bing–Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström’s macroglobulinemia?
2018 · Aikaterini Fitsiori, Luc-Matthieu Fornecker, et al. · European Radiology · 36
High‐dose therapy with autologous stem cells transplantation in Bing‐Neel syndrome: A retrospective analysis of 14 cases
2019 · Laurence Simon, Richard Lemal, et al. · American Journal of Hematology · 13
Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia
2018 · Adrien Contejean, Matthieu Resche-Rigon, et al. · Blood · 12
How we manage patients with Waldenström macroglobulinaemia
2018 · Laurence Simon, Marine Baron, et al. · British Journal of Haematology · 11
PDF
How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy
2019 · Marine Baron, Laurence Simon, et al. · Current Oncology Reports · 9
PDF
Two cases of reversible Fanconi syndrome induced by lenalidomide
2018 · Nadège Wesner, Kevin Bihan, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 9
Waldenström’s macroglobulinemia: The LYSA pragmatic guidelines
2025 · Damien Roos-Weil, Cécile Tomowiak, et al. · European Journal of Cancer · 5
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome
2025 · Romain Stammler, Alexandre Vallée, et al. · The Journal of Allergy and Clinical Immunology In Practice · 5
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
2025 · Anne Quinquenel, Rémi Letestu, et al. · EClinicalMedicine · 4
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
2024 · Anne Sophie Michallet, Remi Letestu, et al. · Blood · 4
Myeloid malignancies with translocation t(4;12)(q11‐13;p13): molecular landscape, clonal hierarchy and clinical outcomes
2021 · Vincent Parinet, Elise Chapiro, et al. · Journal of Cellular and Molecular Medicine · 4
PDF
Positron emission tomography to diagnose chronic Q fever
2015 · L. Simon, S. De Martino, et al. · Médecine et Maladies Infectieuses · 4
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
2021 · Anne-Sophie Michallet, Anne Quinquenel, et al. · Blood · 3
Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.
2025 · Romain Guieze, Emmanuelle Ferrant, et al. · Blood · 2
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
2022 · Anne Quinquenel, Rémi Letestu, et al. · Blood · 1
Is docetaxel (D) less efficient than anthracycline-based chemotherapy (A) in triple-negative breast cancer (TNBC) treated in neoadjuvant setting?
2012 · Laurence Simon, Christine Belletier, et al. · Journal of Clinical Oncology · 1
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
2023 · Anne-Sophie Michallet, Anne Quinquenel, et al. · Blood
PDF
[Waldenström macroglobulinaemia].
2018 · Laurence Simon, Véronique Leblond · PubMed
An unusual case of acute leukemia
2017 · Carole Fleury, Marie Passet, et al. · Annales de biologie clinique
Works count: 31
Citation count: 726
H-index: 10
I10-index: 10
Year
Topic
Type